March 16, 2021 10:52 AM EDT

Roche builds long-term case for Evrysdi with 2-year SMA data; ExeVir nets $50M Series A for llama-derived Covid antibody

Kyle Blankenship

Max Gelman

Senior Editor

Nicole DeFeudis

Editor

At the two-year mark, Roche’s Evrysdi (risdiplam) either maintained or improved motor function from a one-year check-up in patients aged 2 to 25 with Types …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Roche builds long-term case for Evrysdi with 2-year SMA data; ExeVir nets $50M Series A for llama-derived Covid antibody

Kyle Blankenship

Max Gelman

Senior Editor

Nicole DeFeudis

Editor

Sign up to read this article for free.

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

Roche builds long-term case for Evrys­di with 2-year SMA da­ta; Ex­e­Vir nets $50M Se­ries A for lla­ma-de­rived Covid an­ti­body

Senior Editor

Editor

Sign up to read this article for free.

Roche builds long-term case for Evrysdi with 2-year SMA data; ExeVir nets $50M Series A for llama-derived Covid antibody